Lisata Therapeutics
LSTA
43 hedge funds and large institutions have $8.76M invested in Lisata Therapeutics in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 13 closing their positions.
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
16% less funds holding
Funds holding: 51 → 43 (-8)
37% less capital invested
Capital invested by funds: $13.9M → $8.76M (-$5.09M)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
81% less call options, than puts
Call options by funds: $22K | Put options by funds: $117K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$159K |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$83.3K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$73K |
| 4 |
Bank of New York Mellon
New York
|
+$35.1K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$33.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$889K |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$380K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$341K |
| 4 |
Morgan Stanley
New York
|
-$308K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$247K |
LSTA Hedge Fund Activity: Q3 2015 in Review
43 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2015, worth a combined $8.76M — down 37% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of LSTA and 5 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $159K. The largest seller was Sabby Management, exiting entirely with an estimated $889K sold.
- 43 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2015, down from 51 in Q2 2015.
- Funds reported $8.76M of Lisata Therapeutics stock for Q3 2015, down 37% quarter-over-quarter.
- 5 funds opened new Lisata Therapeutics positions in Q3 2015 and 13 closed out, a net change of -8 holders.
- The largest Lisata Therapeutics buyer in Q3 2015 was Vanguard Group, an estimated $159K added.
- The largest Lisata Therapeutics seller in Q3 2015 was Sabby Management, an estimated $889K sold.
Based on aggregated 13F filings for Q3 2015.